Skip to content

SS-31 (Elamipretide)

Phase 2/3 Clinical Trials
peptideInjection

Engineered to target inner mitochondrial membrane via cardiolipin binding. Stabilizes cristae, improves ATP production, and reduces oxidative stress. FDA-approved for Barth syndrome (as Forzinity) — the first FDA-approved mitochondria-targeted therapy.

Key Facts

  • Classification
    SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that concentrates >1000-fold in inner membranes by binding cardiolipin.
  • Primary Benefits
    Longevity (9/10) · Brain & Cognition (7/10) · Muscle Growth (5/10)
  • Administration
    Injection
  • Typical Dose
    4-5 mg subq, 3 times a week on an empty stomach. Clinical trials showed it was safe at 4-40 mg daily for 28 weeks. Most people notice energy improvements within 3-7 days.
  • Evidence Strength
    Moderate — 20 peer-reviewed studies referenced · Community sentiment 10/10
  • Stacks Well With
    NAD+, Epithalon, FOXO4-DRI, MOTS-c
  • Legal Status
    Phase 2/3 Clinical Trials · not prescribable in US

Quick Facts

From price
$80
Type
peptide
Administration
Injection
Evidence
moderate
Studies referenced
20
Community sentiment
10/10
Stacks with
9 peptides
Regulatory
Phase 2/3 Clinical Trials

Top benefits

Longevity
9/10
🧠 Brain & Cognition
7/10
💪 Muscle Growth
5/10
1

Week 1–2

Subtle increase in cellular energy. Improved exercise tolerance if mitochondrial dysfunction is present. Effects are at the cellular level initially.

2

Week 3–6

Noticeable improvement in stamina and energy. Reduced muscle fatigue. Better recovery from physical exertion. Improved mitochondrial biomarkers on labs.

3

Week 8+

Significant mitochondrial optimization. Improved cardiac function in those with dysfunction. Enhanced overall energy metabolism. Potential reversal of age-related mitochondrial decline.

Common Side Effects

Injection site reactionsHeadacheMild GI discomfort
Tolerance: Not well-characterized — addresses structural mitochondrial decline
Cycling: Daily dosing for 8-12 weeks, 4-8 weeks off. Still in clinical trials — follow study protocols.

Scientific Overview

SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that concentrates >1000-fold in inner membranes by binding cardiolipin. Stabilizes cristae, optimizes electron transport efficiency, and reduces ROS. Phase 2/3 trials tested 4-40mg daily. Note: pivotal MMPOWER-3 trial failed its primary endpoint.

Dosing

4-5 mg subq, 3 times a week on an empty stomach. Clinical trials showed it was safe at 4-40 mg daily for 28 weeks. Most people notice energy improvements within 3-7 days.

Reconstitution, storage, injection sites & timing

Benefit Profile

Longevity
9/10
🧠 Brain & Cognition
7/10
💪 Muscle Growth
5/10
🧊 Inflammation
4/10
🔥 Fat Loss
3/10
🩹 Injury Healing
3/10
Medical oversight strongly recommendedNot safe during pregnancy· 2 contraindications